AZD 8329

Drug Profile

AZD 8329

Alternative Names: AZD8329

Latest Information Update: 03 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antihypercalcaemics; Obesity therapies
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 31 Dec 2011 Discontinued - Phase-I for Obesity in Sweden (PO)
  • 31 Dec 2011 Discontinued - Phase-I for Obesity in United Kingdom (PO)
  • 31 Dec 2011 Discontinued - Phase-I for Type-2 diabetes mellitus in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top